Logo image of LAB

STANDARD BIOTOOLS INC (LAB) Stock Fundamental Analysis

NASDAQ:LAB - US34385P1084 - Common Stock

1.245 USD
-0.01 (-1.19%)
Last: 9/2/2025, 9:32:02 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LAB. LAB was compared to 55 industry peers in the Life Sciences Tools & Services industry. While LAB seems to be doing ok healthwise, there are quite some concerns on its profitability. LAB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LAB had negative earnings in the past year.
LAB had a negative operating cash flow in the past year.
In the past 5 years LAB always reported negative net income.
LAB had a negative operating cash flow in each of the past 5 years.
LAB Yearly Net Income VS EBIT VS OCF VS FCFLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

LAB has a worse Return On Assets (-21.64%) than 67.27% of its industry peers.
With a Return On Equity value of -28.38%, LAB is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -21.64%
ROE -28.38%
ROIC N/A
ROA(3y)-34.01%
ROA(5y)-27.97%
ROE(3y)-55.9%
ROE(5y)-53.68%
ROIC(3y)N/A
ROIC(5y)N/A
LAB Yearly ROA, ROE, ROICLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 48.97%, LAB is in line with its industry, outperforming 50.91% of the companies in the same industry.
In the last couple of years the Gross Margin of LAB has declined.
The Profit Margin and Operating Margin are not available for LAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 48.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.13%
GM growth 5Y-2.51%
LAB Yearly Profit, Operating, Gross MarginsLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

4

2. Health

2.1 Basic Checks

LAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LAB has more shares outstanding
LAB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for LAB has been reduced compared to a year ago.
LAB Yearly Shares OutstandingLAB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
LAB Yearly Total Debt VS Total AssetsLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

LAB has an Altman-Z score of -0.43. This is a bad value and indicates that LAB is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.43, LAB is not doing good in the industry: 78.18% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.00 indicates that LAB is not too dependend on debt financing.
LAB has a Debt to Equity ratio of 0.00. This is in the better half of the industry: LAB outperforms 72.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.43
ROIC/WACCN/A
WACC10.62%
LAB Yearly LT Debt VS Equity VS FCFLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 5.16 indicates that LAB has no problem at all paying its short term obligations.
LAB has a better Current ratio (5.16) than 70.91% of its industry peers.
LAB has a Quick Ratio of 4.92. This indicates that LAB is financially healthy and has no problem in meeting its short term obligations.
LAB has a better Quick ratio (4.92) than 76.36% of its industry peers.
Industry RankSector Rank
Current Ratio 5.16
Quick Ratio 4.92
LAB Yearly Current Assets VS Current LiabilitesLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

LAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 64.84%, which is quite impressive.
LAB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.16%.
Measured over the past years, LAB shows a quite strong growth in Revenue. The Revenue has been growing by 8.28% on average per year.
EPS 1Y (TTM)64.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)13.16%
Revenue growth 3Y10.13%
Revenue growth 5Y8.28%
Sales Q2Q%12.79%

3.2 Future

Based on estimates for the next years, LAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.63% on average per year.
Based on estimates for the next years, LAB will show a very negative growth in Revenue. The Revenue will decrease by -15.47% on average per year.
EPS Next Y43.07%
EPS Next 2Y24.87%
EPS Next 3Y18.63%
EPS Next 5YN/A
Revenue Next Year-1.86%
Revenue Next 2Y-17.92%
Revenue Next 3Y-5.01%
Revenue Next 5Y-15.47%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
LAB Yearly Revenue VS EstimatesLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
LAB Yearly EPS VS EstimatesLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LAB. In the last year negative earnings were reported.
Also next year LAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LAB Price Earnings VS Forward Price EarningsLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LAB Per share dataLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as LAB's earnings are expected to grow with 18.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.87%
EPS Next 3Y18.63%

More info and screens

0

5. Dividend

5.1 Amount

LAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STANDARD BIOTOOLS INC

NASDAQ:LAB (9/2/2025, 9:32:02 AM)

1.245

-0.01 (-1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)10-28 2025-10-28
Inst Owners73.06%
Inst Owner ChangeN/A
Ins Owners1.41%
Ins Owner Change40.26%
Market Cap475.59M
Analysts80
Price Target1.94 (55.82%)
Short Float %3.37%
Short Ratio6.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.9%
Min EPS beat(2)-11.39%
Max EPS beat(2)7.59%
EPS beat(4)2
Avg EPS beat(4)-2.03%
Min EPS beat(4)-27.3%
Max EPS beat(4)22.99%
EPS beat(8)2
Avg EPS beat(8)-49.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.53%
Min Revenue beat(2)0.73%
Max Revenue beat(2)4.33%
Revenue beat(4)4
Avg Revenue beat(4)5.28%
Min Revenue beat(4)0.73%
Max Revenue beat(4)8.6%
Revenue beat(8)6
Avg Revenue beat(8)1.75%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-20%
PT rev (3m)-20%
EPS NQ rev (1m)26.67%
EPS NQ rev (3m)-83.33%
EPS NY rev (1m)-12.73%
EPS NY rev (3m)-10.71%
Revenue NQ rev (1m)-55.97%
Revenue NQ rev (3m)-61.54%
Revenue NY rev (1m)-0.67%
Revenue NY rev (3m)-0.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.08
P/FCF N/A
P/OCF N/A
P/B 1.12
P/tB 1.12
EV/EBITDA N/A
EPS(TTM)-0.32
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0.4
BVpS1.11
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.64%
ROE -28.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 48.97%
FCFM N/A
ROA(3y)-34.01%
ROA(5y)-27.97%
ROE(3y)-55.9%
ROE(5y)-53.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.13%
GM growth 5Y-2.51%
F-Score5
Asset Turnover0.28
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.73%
Cap/Sales 8.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.16
Quick Ratio 4.92
Altman-Z -0.43
F-Score5
WACC10.62%
ROIC/WACCN/A
Cap/Depr(3y)31.23%
Cap/Depr(5y)51.75%
Cap/Sales(3y)3.79%
Cap/Sales(5y)6.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)64.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y43.07%
EPS Next 2Y24.87%
EPS Next 3Y18.63%
EPS Next 5YN/A
Revenue 1Y (TTM)13.16%
Revenue growth 3Y10.13%
Revenue growth 5Y8.28%
Sales Q2Q%12.79%
Revenue Next Year-1.86%
Revenue Next 2Y-17.92%
Revenue Next 3Y-5.01%
Revenue Next 5Y-15.47%
EBIT growth 1Y4.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.25%
EBIT Next 3Y31.99%
EBIT Next 5Y19.25%
FCF growth 1Y-61.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.78%
OCF growth 3YN/A
OCF growth 5YN/A